Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?

Abdelazeem, Basel; Abbas, Kirellos Said; Shehata, Joseph; El-Shahat, Nahla Ahmed; Eltaras, Mennatullah Mohamed; Qaddoumi, Ibrahim; Alfaar, Ahmad Samir

doi:10.1002/cam4.5406

Cited by 8 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age-adjusted incidence, limited-duration prevalence rates, incidence-based mortality rate ( 17 , 18 ), and relative survival (RS) ( 19 , 20 ) were calculated using SEER*Stat software, version 8.4.0 (Surveillance Research Program, National Cancer Institute). We calculated the annual percentage change (APC) by fitting a simple linear model, performing regression on the logarithm of the yearly age-adjusted rates, and thereafter, using slope transformation to calculate the APC ( 21 ).…”

Section: Methodsmentioning

confidence: 99%

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA

Wu,

He,

Chang

et al. 2023

Endocrine Connections

View full text Add to dashboard Cite

Background Updated epidemiological data of neuroendocrine tumors are currently lacking. Thus, we performed epidemiological and survival analyses on a large cohort of patients with neuroendocrine tumors and developed a new nomogram to predict survival. Methods This population-based study examined 112,256 patients with neuroendocrine tumors between 2000 and 2018 using data from the Surveillance, Epidemiology, and End Results program. Results The age-adjusted incidence per 100,000 persons of neuroendocrine tumors increased from 4.90 in 2000 to 8.19 in 2018 (annual percentage change, 3.40; 95% confidence interval, 3.13–3.67), with the most significant increases in grade 1, localized stage, and appendix neuroendocrine tumors. The age-adjusted mortality rate increased 3.1-fold from 2000 to 2018 (annual percentage change, 4.14; 95% confidence interval, 3.14–5.15). The 1-, 5-, and 10-year relative survival rates for all neuroendocrine tumors were 80.5%, 68.4%, and 63.5%, respectively. Multivariate analyses showed that male sex; older age; Black, American Indian, and Alaska Native populations; earlier year of diagnosis; lung neuroendocrine tumors; higher grades; and later stage were associated with a worse prognosis and that disease stage and grade were the most important risk factors for prognosis. Furthermore, we established a nomogram to predict the 3-, 5-, and 10-year survival rates, and its discrimination ability was better than that of the TNM classification. Conclusions The incidence, prevalence, and mortality rate of neuroendocrine tumors continued to increase over the last two decades. Additionally, the nomogram could accurately quantify the risk of death in patients with neuroendocrine tumors and had good clinical practicability.

show abstract

Section: Methodsmentioning

confidence: 99%

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA

Wu,

He,

Chang

et al. 2023

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…Treatment Treatment modalities for Rb have changed rapidly over the past decade [40] . and the survival of many Rb cases that used to die in the past has improved in recent years [3,[57][58][59] . In general, the available treatment options for Rb include surgery (including enucleation and pars plana vitrectomy); focal therapies (including cryotherapy, laser photocoagulation, and transpupillary thermotherapy); chemotherapy (including intravenous chemotherapy, intra-arterial chemotherapy, and intravitreal chemotherapy), and radiotherapy (including plaque brachytherapy and external beam technique) [16] .…”

Section: Rb Prognosis and Screeningmentioning

confidence: 99%

“…Therefore, most cases of Rb are unilateral [1] . In the USA, 69.6% of the Rb cases are unilateral [3] .…”

Section: Introductionmentioning

confidence: 99%

Epidemiological aspect of retinoblastoma in the world: a review of recent advance studies

et al. 2023

View full text Add to dashboard Cite

AIM: To collect and present updated evidence about epidemiological aspects of retinoblastoma (Rb) in the world. METHODS: A comprehensive search without the time and language restrictions was conducted in international databases, including MEDLINE, Scopus, Web of Science, and PubMed. The search keywords were “retinoblastoma” OR “retinal Neuroblastoma” OR “retinal glioma” OR “retinoblastoma eye cancer” OR “retinal glioblastoma”. RESULTS: The worldwide incidence of Rb is 1 in 16 000-28 000 live births, but was higher in developing compared to developed countries. Several attempts for improving early detection and treatment had increased the Rb survival rate from 5% to 90% in developed countries over the past decade, but its survival was lower in developing countries (about 40% in low-income countries) and the majority of mortalities occurred in developing countries. The etiology of Rb could be viewed as genetics in the heritable form and environmental and lifestyle factors in the sporadic form. Some environmental risk factors such as in vitro fertilization; insect sprays; father’s occupational exposure to oil mists in metal working, and poor living conditions might play a role in the occurrence of the disease. Although ethnicity might affect Rb incidence, sex has no documented effect and the best treatment approaches were now ophthalmic artery chemosurgery and intravitreal chemotherapy. CONCLUSION: Determining the role of genetics and environmental factors helps to accurately predict the prognosis and identify the mechanism of the disease, which can reduce the risk of tumor development.

show abstract

Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?

et al. 2022

View full text Add to dashboard Cite

Introduction: Retinoblastoma (RB) is the most common primary intraocular cancer of childhood. Over the last few decades, a variety of techniques and treatment modalities emerged that improved the survival and ocular salvage rate of patients with RB. We investigated the relative survival trends of patients with RB from 2000 to 2018 by using the Surveillance, Epidemiology, and End Results (SEER) database.Design: Retrospective database review. Methods:We extracted data from SEER 18 from 2000 to 2018. All patients with clinically diagnosed RB during the study period were included. We utilized SEER*Stat 8.3.9 and JPSurv software to estimate relative 5-and 10-year survival rates and trends and generated descriptive analyses with IBM SPSS. Main Outcome Measures:Patient survival rates at 5-and 10-year after RB diagnosis.Results: RB was diagnosed in 1479 patients within the SEER 18 Program during our study period. The cohort comprised 776 (52.5%) males, 615 (41.6%) non-Hispanic whites, 487(32.9%) Hispanics, 1030 (69.6%) patients with unilateral disease, and 1087 (73.5%) patients with localized disease. Relative survival trends at 5-and 10-year significantly declined over the study periods (−0.42%, and −0.50% annually, respectively) but the decline was not significant in unilateral and bilateral RB cases separately. Conclusions:Five-and ten-year relative survival trends declined from 2000 to 2018 and were significantly decreasing. Further studies that include more patients are needed to identify the factors contributing to reduced survival of patients with RB over time.

show abstract

Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?

Cited by 8 publications

References 38 publications

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA

Epidemiological aspect of retinoblastoma in the world: a review of recent advance studies

Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?

Contact Info

Product

Resources

About